181 related articles for article (PubMed ID: 36115844)
1. Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Yang Y; Bolomsky A; Oellerich T; Chen P; Ceribelli M; Häupl B; Wright GW; Phelan JD; Huang DW; Lord JW; Van Winkle CK; Yu X; Wisniewski J; Wang JQ; Tosto FA; Beck E; Wilson K; McKnight C; Travers J; Klumpp-Thomas C; Smith GA; Pittaluga S; Maric I; Kazandjian D; Thomas CJ; Young RM
Nat Commun; 2022 Sep; 13(1):5469. PubMed ID: 36115844
[TBL] [Abstract][Full Text] [Related]
2. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
3. Dynamin-dependent amino acid endocytosis activates mechanistic target of rapamycin complex 1 (mTORC1).
Shibutani S; Okazaki H; Iwata H
J Biol Chem; 2017 Nov; 292(44):18052-18061. PubMed ID: 28808055
[TBL] [Abstract][Full Text] [Related]
4. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
5. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
6. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling.
Wang X; Fonseca BD; Tang H; Liu R; Elia A; Clemens MJ; Bommer UA; Proud CG
J Biol Chem; 2008 Nov; 283(45):30482-92. PubMed ID: 18676370
[TBL] [Abstract][Full Text] [Related]
7. The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.
Xie CM; Tan M; Lin XT; Wu D; Jiang Y; Tan Y; Li H; Ma Y; Xiong X; Sun Y
Cell Rep; 2019 Mar; 26(11):3037-3050.e4. PubMed ID: 30865892
[TBL] [Abstract][Full Text] [Related]
8. Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Yang Y; Bolomsky A; Oellerich T; Chen P; Ceribelli M; Häupl B; Wright GW; Phelan JD; Huang DW; Lord JW; Van Winkle CK; Yu X; Wisniewski J; Wang JQ; Tosto FA; Beck E; Wilson K; McKnight C; Travers J; Klumpp-Thomas C; Smith GA; Pittaluga S; Maric I; Kazandjian D; Thomas CJ; Young RM
Nat Commun; 2022 Oct; 13(1):5830. PubMed ID: 36192480
[No Abstract] [Full Text] [Related]
9. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
[TBL] [Abstract][Full Text] [Related]
10. Suppression of mTORC1 activity in senescent Ras-transformed cells neither restores autophagy nor abrogates apoptotic death caused by inhibition of MEK/ERK kinases.
Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Aging (Albany NY); 2018 Nov; 10(11):3574-3589. PubMed ID: 30482887
[TBL] [Abstract][Full Text] [Related]
11. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1.
Sancak Y; Peterson TR; Shaul YD; Lindquist RA; Thoreen CC; Bar-Peled L; Sabatini DM
Science; 2008 Jun; 320(5882):1496-501. PubMed ID: 18497260
[TBL] [Abstract][Full Text] [Related]
12. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence.
Wang W; Chen JX; Liao R; Deng Q; Zhou JJ; Huang S; Sun P
Mol Cell Biol; 2002 May; 22(10):3389-403. PubMed ID: 11971971
[TBL] [Abstract][Full Text] [Related]
13. Amino acid regulation of TOR complex 1.
Avruch J; Long X; Ortiz-Vega S; Rapley J; Papageorgiou A; Dai N
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E592-602. PubMed ID: 18765678
[TBL] [Abstract][Full Text] [Related]
14. TFEB-driven endocytosis coordinates MTORC1 signaling and autophagy.
Nnah IC; Wang B; Saqcena C; Weber GF; Bonder EM; Bagley D; De Cegli R; Napolitano G; Medina DL; Ballabio A; Dobrowolski R
Autophagy; 2019 Jan; 15(1):151-164. PubMed ID: 30145926
[TBL] [Abstract][Full Text] [Related]
15. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids.
Sancak Y; Bar-Peled L; Zoncu R; Markhard AL; Nada S; Sabatini DM
Cell; 2010 Apr; 141(2):290-303. PubMed ID: 20381137
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation.
Carrière A; Cargnello M; Julien LA; Gao H; Bonneil E; Thibault P; Roux PP
Curr Biol; 2008 Sep; 18(17):1269-77. PubMed ID: 18722121
[TBL] [Abstract][Full Text] [Related]
17. Genetic dissection of Ragulator structure and function in amino acid-dependent regulation of mTORC1.
Nada S; Okada M
J Biochem; 2020 Dec; 168(6):621-632. PubMed ID: 32653916
[TBL] [Abstract][Full Text] [Related]
18. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
19. Regulation of mTORC1 by Upstream Stimuli.
Melick CH; Jewell JL
Genes (Basel); 2020 Aug; 11(9):. PubMed ID: 32854217
[TBL] [Abstract][Full Text] [Related]
20. Amino acids activate mammalian target of rapamycin (mTOR) complex 1 without changing Rag GTPase guanyl nucleotide charging.
Oshiro N; Rapley J; Avruch J
J Biol Chem; 2014 Jan; 289(5):2658-74. PubMed ID: 24337580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
